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Abstract
Background: We previously reported that fenugreek (Trigonella foenum-graecum L.) improved diet-induced
metabolic disorders in rats. The purpose of the present study was to examine the dose-dependent effects, safety
and tolerability of fenugreek.
Methods: The diets used in this study were the high-fat high-sucrose diet (HFS; lard 50%kcal, sucrose 25%kcal) as a
control (Ctrl group) or the HFS containing 0.25% (VL group), 1.25% (L group), 2.50% (M group), 5.00% (H group) or
12.30% (VH group) fenugreek based on the modified version of the AIN-93G purified diet.
Results: Fenugreek dose-dependently reduced the hepatic triglyceride and total cholesterol levels. Fenugreek also
dose-dependently increased the excretion of cholesterol and total bile acids into the feces. However, the glucose
tolerance showed no significant change by fenugreek administration. The VL and L groups did not significantly
change triglyceride or total cholesterol levels in the liver. The VL group showed no increase in excretion of
triglyceride, total cholesterol or bile acids in the feces. The VH group showed appetite reduction and diarrhea,
while no adverse effect or symptoms were observed in the M group.
Conclusion: These results suggest that fenugreek inhibited lipid accumulation in the liver by increasing the lipid
excretion in the feces. The effective, safe and tolerable dose of fenugreek was found to be around 2.50% (w/w).
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Background
Recently, the incidence of lifestyle-related diseases
including metabolic disorders has been expanding in
parallel with rapid economic development in advanced
countries. The principle therapeutic policy for these dis-
eases lies in the improvement of dietary habits and the
increase of physical activity. However, it is difficult to
control and modify one’s usual life style. In that case,
functional foods with preventive and therapeutic effects
on metabolic disorders are very helpful for the improve-
ment of lifestyle-related diseases. On the other hand, the
excessive intake of some functional foods may result in
adverse effects. However, a lot of such functional foods
are actually available at the market, though their safety
has not been confirmed [1].
It has been reported that the active components of
fenugreek, 4-hydroxyisoleucine and galactomannan, low-
ered blood glucose levels and improved lipid metabolism
in vivo [2-5]. Fenugreek also contains dioscin, a steroidal
saponin, and trigonelline, an alkaloid. These phytoestro-
gens have estrogen-like activities in vitro [6,7]. In addi-
tion, fenugreek contains a large quantity of insoluble
dietary fibers. These active components might cause sev-
eral adverse reactions including hypoglycemia, diarrhea
and galactorrhea, when an excessive amount of fenu-
greek was ingested [2,8,9].
The purpose of this study was to examine the dose-
dependent effects, safety and tolerability of fenugreek.
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Animals and housing
Three-week-old male, Sprague-Dawley rats were obtained
from CLEA (Tokyo, Japan). Rats were housed individually
in stainless steel wire-bottom cages in a room maintained
at 22 ± 2 °C and 55 ± 5% relative humidity with a 12 h
cycle of light and dark. Rats were given free access to tap
water throughout the experiment. They were fed a com-
mercial diet (CE-2; CLEA) for 1 wk prior to the experi-
ment. The experimental protocol was approved by the
Institutional Animal Care and Use Committee of Josai
University.
Experimental design
The rats were randomly divided into six groups of 6 rats
each. Each group was fed either the high-fat high-sucrose
diet (HFS; lard 50%kcal, sucrose 25%kcal) based on the
modified version of the AIN-93G [10] as a control (Ctrl
group) or the HFS containing 0.25% (VL group), 1.25%
(L group), 2.50% (M group), 5.00% (H group) or 12.30%
(VH group) fenugreek seeds powder (Gaban Co., Tokyo,
Japan) for 12 wks (Table 1). Almost the same energy
intake was maintained for all groups by adjusting the diet-
ary intake, and the food consumption in all groups except
for the VH group was approximately equivalent to the ad
libitum consumption under these conditions. After 12
wks, the rats were individually transferred into the meta-
bolic cage, and urine and feces were separately collected
for 1 day. At the end of the experiment, the rats were
killed with pentobarbital sodium (100 mg/kg, ip). Blood
samples were collected from the abdominal aorta, and the
plasma was separated after centrifugation (2,000 × g for 20
min at 4°C) and stored at -30°C until analyzed. After the
collection of the blood sample, the liver, interscapular
brown adipose tissue (IBAT) and epididymal white adi-
pose tissue (EWAT) were immediately excised, weighed
and stored at -30°C for further analyses.
Oral glucose tolerance tests and intraperitoneal insulin
tolerance tests
At the 10th wk, the rats were deprived of food for 12 h.
Then they were given oral glucose (2 g/kg body weight)
for the oral glucose tolerance test (OGTT) and an intra-
peritoneal injection of human regular insulin (0.75 U/kg
body weight) for the intraperitoneal insulin tolerance test
(IPITT). Blood glucose concentrations were measured by
Ascensia™ DexterZII (Bayer Medical, Tokyo, Japan)
using tail blood samples at 0, 30, 60 and 120 min after
glucose administration and at 0, 15, 30, 45, 60 and
120 min after insulin administration. Plasma insulin con-
centrations were measured using a commercial kit (Rat
Insulin ELISA kit, Shibayagi Co., Gunma, Japan) using
separated tail plasma samples at 0, 30, 60 and 120 min
after glucose administration.
Blood analysis
Plasma triglyceride, total cholesterol, AST and ALT
were measured by colorimetric slides using the Fuji Dri-
Chem 3500 (Fujifilm Corp., Tokyo, Japan).
Hepatic and fecal lipids concentrations
The hepatic and fecal lipids were extracted in accordance
with the method of Bligh and Dyer [11] and the method of
Folch [12], respectively. Each extract was solubilized by
Triton-X100 (Wako Pure Chemical Industries, Osaka,
Japan), and the lipids concentrations were determined
enzymatically by means of commercial kits (Triglycerides
E-Test Wako, Cholesterol E-Test Wako, Total Bile Acid
Test Wako; Wako Pure Chemical Industries).
Statistical analysis
All data are expressed as the mean ± SEM. Statistical
analyses were carried out using Statistical Package for
Social Sciences (SPSS12.0J for Windows; SPSS Japan,
Tokyo, Japan). In the three-group comparison, the
Table 1 Experimental diets
1
(g) Ctrl VL L M H VH
Lard
2 260.450 260.300 258.100 255.780 251.000 237.700
Milk casein
2 267.100 266.380 261.900 256.700 246.380 216.500
Sucrose
2 316.700 316.700 314.700 312.900 309.100 298.600
b-Corn starch
2 57.698 57.170 55.136 52.343 47.019 31.577
Vitamin mixture
3 10.000 10.000 10.000 10.000 10.000 9.838
Mineral mixture
4 35.000 34.923 34.613 34.225 33.450 30.621
Cellulose powder
2 50.000 48.975 50.000 50.000 50.000 49.190
L-Cystin
5 3.000 3.000 3.000 3.000 3.000 2.951
t-Butylhydroquinone
5 0.052 0.052 0.052 0.052 0.051 0.050
Fenugreek
6 - 2.500 12.500 25.000 50.000 122.974
Ctrl: Control group, VL: Very low dose of fenugreek group (0.25%), L: Low dose of fenugreek group (1.25%), M: Middle dose of fenugreek group (2.5%), H: High
dose of fenugreek group (5.0%), VH: Very high dose of fenugreek group (12.3%).
1Based on the AIN-93G and modified.
2,3,4Purchased from Oriental Yeast Co.,
Tokyo, Japan.
3Vitamin mixture was based on the AIN-93 formation, and added with tartaric acid choline.
4Mineral mixture was based on the AIN-93G formation.
5Purchased from Wako Pure Chemical Industries, Osaka, Japan.
6Purchased from Gaban Co., Tokyo, Japan.
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sis of variance (ANOVA), and the differences among
means were tested by means of the Tukey’s honestly sig-
nificant difference (HSD) test. In the two-group compar-
ison, the effects of treatment were analyzed through a
T-test. In OGTT and IPITT, the effects of treatment
were analyzed by means of repeated ANOVA. Differ-
ences were considered significant at P < 0.05.
Results
Effect of fenugreek on the body weight, energy intake,
tissue weights and plasma parameters
T h eb o d yw e i g h tg a i n ,t h eE W A Tw e i g h ta n dt h eI B A T
weight decreased significantly in the VH group compared
to the other groups. No significant difference was found in
the liver weight among the groups (Table 2).
No significant difference was found in AST, ALT levels
or AST/ALT in the liver amongt h eg r o u p s( T a b l e2 ) .
Thus fenugreek intake did not show any liver injury.
Effects of fenugreek on glucose tolerance
The fasting blood glucose levels decreased significantly in
the M and VH groups compared to the Ctrl group,
whereas no significant difference was found in the fasting
plasma insulin levels or insulin resistance index, HOMA-
IR (homeostasis model assessment as an index of insulin
resistance), among groups (Table 3).
In OGTT, the blood glucose levels at 120 min in the
VH group were significantly lower than those in the
Ctrl group (Figure 1A), and the plasma insulin levels at
120 min in the VH group were significantly lower than
those in other groups (Figure 1B). There was no signifi-
cant difference of the area under the curve (AUC) of
glucose among the groups (Figure 1C), but the VH
group showed significant lower AUC of insulin com-
pared to the Ctrl group (Figure 1D).
In IPITT, the blood glucose levels at 60 and 120 min
in the VH group were significantly lower than those of
the other groups (Figure 2A). AUC of the blood glucose
in the VH group was also significantly lower than those
of the other groups (Figure 2B).
Lipids and bile acid levels in plasma, liver and feces
Although the plasma triglyceride and total cholesterol
levels increased slightly in some groups, no dose depen-
dent effect was found (Table 2). However, the hepatic
triglyceride and total cholesterol levels decreased signifi-
cantly in the M and VH groups compared to the Ctrl
group (Figure 3). In feces, the triglyceride levels in the
VH group increased remarkably compared to the levels
the in the other groups. The total cholesterol levels
increased significantly in the L group, the H group and
the VH group compared to the Ctrl group. Fenugreek
elevated the total bile acid levels in feces in a dose-
dependent manner (Figure 4).
Discussion
Hepatic steatosis is a risk factor for liver cirrhosis and
atherosclerosis. Both the liver and adipocytes play a
major role in the regulation of cellular and circulating
serum lipids, predominantly triglyceride and cholesterol.
In our previous studies, fenugreek decreased the hepatic
triglyceride and total cholesterol levels in normal rats
fed with a high-fat high-sucrose diet [13,14]. The pre-
sent study investigated dose-dependent effects of fenu-
greek and its safety and tolerability.
The body weight gain and EWAT and IBAT weights in
the VH group decreased significantly as compared with
all of the other groups. In a pair feeding procedure, the
VH group showed slightly less food intake than the other
groups. It has been reported that the reduced food intake
in the presence of soluble fibers such as galactomannan
Table 2 Effect of fenugreek on the body weight, energy intake, tissue weights and plasma
(g) Ctrl VL L M H VH
Body weight gain (g) 500.6 ± 18.5
a 491.2 ± 10.2
a 486.7 ± 18.5
a 463.9 ± 10.2
a 480.6 ± 18.5
a 408.4 ± 10.2
b
EER
1 (mg/kJ) 15.6 ± 0.3
a 15.3 ± 0.1
a 15.6 ± 0.3
a 14.6 ± 0.2
ab 15.4 ± 0.3
a 13.4 ± 0.5
b
Liver weight (g) 19.3 ± 1.1 20.0 ± 0.6 18.3 ± 0.7 17.2 ± 0.6 18.0 ± 0.8 17.3 ± 1.0
EWAT
2 weight (g) 15.3 ± 0.5
a 15.9 ± 0.9
a 13.6 ± 0.7
ab 14.5 ± 0.7
a 16.3 ± 1.4
a 10.1 ± 1.0b
IBAT
3 weight (g) 0.77 ± 0.04 0.76 ± 0.04 0.74 ± 0.05 0.83 ± 0.05 0.78 ± 0.08 0.55 ± 0.03*
Plasma TG
4 (mmol/L) 1.64 ± 0.51 1.98 ± 0.61 2.06 ± 0.29 1.79 ± 0.29 3.63 ± 0.73 2.47 ± 0.46*
Plasma TC
5 (mmol/L) 1.50 ± 0.14 1.94 ± 0.14 1.73 ± 0.17 1.83 ± 0.17* 1.72 ± 0.13 1.70 ± 0.12
AST (U/L) 66.2 ± 8.0 76.2 ± 10.6 94.3 ± 21.7 98.5 ± 25.7 67.7 ± 9.1 74.8 ± 8.2
ALT (U/L) 17.3 ± 0.7 21.2 ± 3.2 22.5 ± 3.9 25.0 ± 4.6 19.2 ± 2.4 22.2 ± 1.4
AST/ALT
6 1.08 ± 0.11 1.03 ± 0.04 1.14 ± 0.06 1.05 ± 0.08 1.02 ± 0.09 0.95 ± 0.07
Ctrl: Control group, VL: Very low dose of fenugreek group (0.25%), L: Low dose of fenugreek group (1.25%), M: Middle dose of fenugreek group (2.5%), H: High
dose of fenugreek group (5.0%), VH: Very high dose of fenugreek group (12.3%).
1EER (mg/kJ) = Body weight gain (mg)/Total food intake (kJ).
2EWAT: Epididymal
white adipose tissue.
3IBAT: Interscapular brown adipose tissue.
4TG: Triglyceride.
5TC: Total cholesterol.
6The relative values for Normal rats’ data; AST/ALT = AST
(U/L)/ALT (U/L)/Normal rats’ data. Values are expressed as means ± SEM for 6 rats. Means without a common superscript letter are significantly different, P < 0.05
(ANOVA). Asterisks indicate a difference from Ctrl: P < 0.05 (t-test).
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emptying and promoting satiety. In our study, the ratio
of body weight gain to food intake was similar among the
groups [5]. However, the VH group showed significant
lower levels of the energy efficiency ratio (EER) compared
to the Ctrl group. Therefore, we suspect that the
decreases in body and tissue weight were caused by the
decrease of EER rather than the decrease in energy
intake.
Fenugreek dose-dependently reduced the hepatic tri-
glyceride and total cholesterol levels. Whereas the fecal
triglyceride excretion levels rose significantly only in the
VH group, fenugreek dose-dependently augmented the
fecal total cholesterol and the bile acid excretion levels.
The plasma triglyceride and total cholesterol levels were
not significantly different among the groups. These
results suggest that the mechanism underlying the inhi-
bition of lipid accumulation in the liver and the adipose
tissue would have enhanced the total cholesterol and
the bile acid excretion in feces. Likewise, the increase of
triglyceride excretion led to these results in the VH
group.
Saponins, such as diosgenin contained in fenugreek,
form large micells from bile acid and saponin molecules
in the small intestine, and these micelles inhibit the cho-
lesterol absorption by directly excreting cholesterol in
feces [15,16]. Diosgenin also reduces the triglyceride con-
tent and mRNA expression levels of lipogenic genes
(FAS, SCD-1 and ACC) and suppresses LXRa transacti-
vation. This leads to down-regulation of both the mRNA
and protein expression levels of SREBP-1c in HepG2
cells [17]. These results obtained from the previous
reports supported that fenugreek attenuated lipid accu-
mulation in the liver by down-regulating lipid synthesis
as well as increasing lipid excretion in the feces.
The fasting blood glucose levels decreased significantly
in the M and VH groups as compared with the Ctrl group,
but the fasting plasma insulin levels did not differ signifi-
cantly among the fenugreek-administered groups as com-
pared with the Ctrl group. HOMA-IR was not significantly
different among the groups. Therefore, in these experi-
ments, fenugreek did not affect the glucose tolerance.
However, some improving effects on the glucose metabo-
lism and glucose tolerance of fenugreek have been
reported. For example, 4-hydroxyisoleucin contained in
fenugreek stimulates insulin secretion [2,18]. In OGTT in
our experiment, the fenugreek administration did not
Table 3 Insulin resistance index
(g) Ctrl VL L M H VH
Fasting blood glucose (mmol/L) 6.27 ± 0.24
a 6.19 ± 0.22
ac 5.50 ± 0.28
ab 5.20 ± 0.15b
c 5.60 ± 0.34
ab 5.03 ± 0.11
b
Fasting blood insulin (pmol/L) 129 ± 37 167 ± 35 56 ± 27 117 ± 29 94 ± 33 54 ± 10
HOMA-IR
1 1.00 ± 0.28 1.69 ± 0.49 0.85 ± 0.52 0.78 ± 0.20 0.98 ± 0.36 0.35 ± 0.06
Ctrl: Control group, VL: Very low dose of fenugreek group (0.25%), L: Low dose of fenugreek group (1.25%), M: Middle dose of fenugreek group (2.5%), H: High
dose of fenugreek group (5.0%), VH: Very high dose of fenugreek group (12.3%).
1Relative values of (fasting blood glucose × fasting blood insulin) compared to
the mean value of the Ctrl group. Values are expressed as means ± SEM for 6 rats. Means without a common superscript letter are significantly different, P<
0.05 (ANOVA).
Figure 1 Effect of fenugreek on the plasma insulin and blood
glucose levels in OGTT. Changes of blood glucose [A], changes of
plasma insulin [B], AUC of blood glucose [C], AUC of plasma insulin
[D] after oral glucose load (2 g/kg). Ctrl: Control group [○], VL: Very
low dose of fenugreek group (0.25%) [●], L: Low dose of fenugreek
group (1.25%)[▲], M: Middle dose of fenugreek group (2.5%) [■], H:
High dose of fenugreek group (5.0%) [×], VH: Very high dose of
fenugreek group (12.3%)[+]. Values are expressed as means for 6
rats [A,B]. Values are expressed as means ± SEM for 6 rats [C,D].
Asterisks indicate a difference from Ctrl: P < 0.05 (t-test).
Figure 2 Effect of fenugreek on blood glucose levels in IPITT.
Changes of blood glucose [A] and AUC [B] after intraperitoneal
insulin load (0.75 U/kg). Ctrl: Control group [○], VL: Very low dose of
fenugreek group (0.25%) [●], L: Low dose of fenugreek group
(1.25%)[▲], M: Middle dose of fenugreek group (2.5%) [■], H: High
dose of fenugreek group (5.0%) [×], VH: Very high dose fenugreek
group (12.3%)[+]. Values are expressed as means for 6 rats [A].
Values are expressed as means ± SEM for 6 rats [B]. Means without
a common superscript letter are significantly different, P < 0.05
(ANOVA). Asterisks indicate a difference from Ctrl: P < 0.05 (t-test).
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cose levels except at 120 min in the VH group. Further,
fenugreek inhibited insulin secretion only in the VH
group. It has been reported that fenugreek also enhances
insulin sensitivity through the activation of insulin signal-
ing at an early stage in peripheral tissues and liver [19].
This effect is brought by the activation of glucose and lipid
metabolism with up-regulation of several enzymes [19-23]
and the increase of glycogen synthesis in the muscle and
liver [22-24]. In addition, diosgenin enhances the peroxi-
some proliferator-activated receptor-g (PPARg) level in
EWAT and promotes both the adipocyte differentiation
and the size reduction. As a result, the secretion of mono-
cyte chemoattractant protein-1 (MCP-1) in adipocytes is
suppressed, while the secretion of adiponectin is pro-
moted, and the inflammation in adipose tissue is inhibited
[18,25]. Therefore, we assume that fenugreek activated
firstly insulin sensitivity rather than insulin secretion in
the relatively mild metabolic disorders we generated in
rats through high-fat high-sucrose diets. The VH group
showed appetite reduction and diarrhea, while no rats in
the M group showed any adverse effects or symptoms.
These results suggest that fenugreek dose-dependently
inhibited lipid accumulation in the liver by increasing
the lipid and bile acids excretion in the feces, and that
an effective, safe and tolerable dose of fenugreek was
around 2.50% (w/w).
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